CONCLUSION : Our results showed that preemptive antiviral therapy can reduced the risk of acute and overall deterioration of hepatic function. In this regard, preemptive antiviral therapy should be administered during TACE. Prevent deterioration of hepatic function by preemptive antiviral therapy may facilitate continuing anti-cancer therapy and improve long term outcomes. Disclosures: The following people have nothing to disclose: Sun Hong Yoo, Jeong Won Jang, Jung Hyun Kwon, Kyu Won Chung Introduction Current first line options for the treatment of chronic hepatitis B (CHB) involve the use of either Pegylated interferon-α(Peg-IFN) or nucleos(t)ide analogue
therapy. There is DNA Damage inhibitor increasing interest in the potential benefits of combining these two classes, particularly in relation to improving the rates of HBsAg clearance,
a rare but highly desirable endpoint. The aim of this study check details was to examine the efficacy and safety of combining Peg-IFN with Tenofovir TDF in HBeAg positive CHB patients. Methods In this prospective multicenter study, HBeAg positive CHB patients were randomized in a 1:1:1 ratio to receive either Peg-IFN monotherapy 1 80mcg sc weekly (Peg-IFN) for 48 weeks, (2) Peg-IFN and TDF (300mg daily) combination ther-apy(PEG-TDF) for 48 weeks or (3) ‘lead in’ therapy with Peg-IFN for 24 weeks followed by combination therapy for 24 weeks and then another 24 weeks of TDF alone. Patients were then followed up for 24 weeks off treatment. Baseline data included patient demographics, liver histology and HBV genotype. On treatment data included HBV DNA viral load, quantitative HBsAg and HBeAg titres, routine biochemistry, serum calcium PJ34 HCl and phosphate and adverse events. The primary end-point was the loss of HBsAg, while secondary endpoints included HBV DNA <20 IUml, HBeAg seroconversion and normalization of ALT. Results Twenty seven patients have been enrolled to date with the baseline characteristics of all 3 treatment groups (Peg-IFN, Peg+TDF and lead-in) comparable in terms of mean age (3 1,29,
32 years), median ALT (1 07, 1 12, 86 U/L) and HBV DNA viral load (7.2, 7.7 and 7.7 log 10 IU/ml). 26 of 27 patients were of Asian ethnicity and one patient in each group had Metavir fibrosis >3. An interim analysis of the end of treatment outcomes of 15 patients who have completed a minimum of 48 weeks of therapy is presented here. No patient achieved the primary endpoint of HBsAg loss and no significant differences were noted in the on-treatment kinetics of HBsAg levels between the 3 groups. HBV DNA suppression <20 IU/ml was observed in 1, 4 and 2 patients in the Peg-IFN, Peg+TDF and lead-in groups respectively. HBeAg to anti-HBe seroconversion was achieved in 2,3 and 1 patient respectively.